{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:54:13Z","timestamp":1788540853324,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T00:00:00Z","timestamp":1295395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s11936-011-0112-2","type":"journal-article","created":{"date-parts":[[2011,1,17]],"date-time":"2011-01-17T22:04:29Z","timestamp":1295301869000},"page":"159-168","source":"Crossref","is-referenced-by-count":7,"title":["Approach to Venous Thromboembolism in the Cancer Patient"],"prefix":"10.1007","volume":"13","author":[{"given":"Andrea","family":"Piccioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Prandoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,19]]},"reference":[{"key":"112_CR1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","volume":"6","author":"P Prandoni","year":"2005","unstructured":"Prandoni P, Falanga A, Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 2005, 6:401\u2013410.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"112_CR2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6605599","volume":"102","author":"S Noble","year":"2010","unstructured":"Noble S, Pasi J: Epidemiology and pathophysiology of cancer associated thrombosis. Br J Cancer 2010, 102(Suppl 1):S2\u2013S9.","journal-title":"Br J Cancer"},{"key":"112_CR3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJ, Osanto S, et al.: Malignancy, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005, 293:715\u2013722.","journal-title":"JAMA"},{"issue":"5","key":"112_CR4","first-page":"437","volume":"84","author":"P Prandoni","year":"1999","unstructured":"Prandoni P, Piccioli A, Girolami A: cancer and venous thromboembolism: an overview. Haematologica 1999, 84(5):437\u2013445.","journal-title":"Haematologica"},{"key":"112_CR5","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AWA, Piccioli A: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002, 100:3484\u20133488.","journal-title":"Blood"},{"key":"112_CR6","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","volume":"18","author":"BA Hutten","year":"2000","unstructured":"Hutten BA, Prins MH, Gent M, et al.: Incidence of recurrent thromboembolic or bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000, 18:3078\u20133083.","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"112_CR7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1378\/chest.08-0658","volume":"133","author":"C Kearon","year":"2008","unstructured":"Kearon C, Kahn SR, Agnelli G, et al.: Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(Suppl 6):454\u2013545.","journal-title":"Chest"},{"issue":"Suppl 5","key":"112_CR8","first-page":"V275","volume":"21","author":"M Mandala\u2019","year":"2010","unstructured":"Mandala\u2019 M, Falanga A, Roila F, et al.: Venous thromboembolism in cancer patients: ESMO clinical practice guidelines for the management. Ann Oncol 2010, 21(Suppl 5):V275\u2013V276.","journal-title":"Ann Oncol"},{"key":"112_CR9","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","volume":"25","author":"GH Lyman","year":"2007","unstructured":"Lyman GH, Khorana AA, Falanga A, et al.: American Society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007, 25:5490\u20135505.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"112_CR10","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1007\/s11739-010-0445-y","volume":"5","author":"P Prandoni","year":"2010","unstructured":"Prandoni P: The treatment of venous thromboembolism in patients with cancer. Intern Emerg Med 2010, 5(Suppl 1):S27\u2013S30.","journal-title":"Intern Emerg Med"},{"issue":"Suppl 1","key":"112_CR11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1538-7836.2009.03415.x","volume":"7","author":"SZ Goldhaber","year":"2009","unstructured":"Goldhaber SZ: Advanced treatment strategies for acute PE, including thrombolysis and embolectomy. J Thromb Haemost 2009, 7(Suppl 1):322\u2013327.","journal-title":"J Thromb Haemost"},{"key":"112_CR12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.8-4-381","volume":"8","author":"AK Kakkar","year":"2003","unstructured":"Kakkar AK, Levine M, Pinedo HM, et al.: Venous thrombosis in cancer patients: insights from the Frontline survey. Oncologist 2003, 8:381\u2013388.","journal-title":"Oncologist"},{"key":"112_CR13","first-page":"CD001100","volume":"4","author":"CJ Dongen Van","year":"2004","unstructured":"Van Dongen CJ, van den Belt AG, Prins MH, et al.: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004, 4:CD001100.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"112_CR14","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1038\/sj.bjc.6605601","volume":"102","author":"R Coleman","year":"2010","unstructured":"Coleman R, MacCallum P: Treatment and secondary prevention of venous thromboembolism in cancer. Br J Cancer 2010, 102(Suppl 1):S17\u2013S23.","journal-title":"Br J Cancer"},{"key":"112_CR15","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.23814","volume":"113","author":"EA Aki","year":"2008","unstructured":"Aki EA, Rohilla S, Barba M, et al.: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. Cancer 2008, 113:1685\u20131694.","journal-title":"Cancer"},{"issue":"12","key":"112_CR16","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1517\/14656566.2010.494181","volume":"11","author":"M Panova-Noema","year":"2010","unstructured":"Panova-Noema M, Falanga A: Treatment of thromboembolism in cancer patients. Expert Opin Pharmacother 2010, 11(12):2049\u20132058.","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 4","key":"112_CR17","doi-asserted-by":"crossref","first-page":"IV136","DOI":"10.1093\/annonc\/mdi923","volume":"16","author":"S Siragusa","year":"2005","unstructured":"Siragusa S, Arcara C, Malato A, et al.: Home therapy for deep venous thrombosis and pulmonary embolism in patients with cancer. Ann Oncol 2005, 16(Suppl 4):IV136\u2013IV139.","journal-title":"Ann Oncol"},{"key":"112_CR18","first-page":"220","volume":"90","author":"W Ageno","year":"2005","unstructured":"Ageno W, Grimwood R, Limbiati S, et al.: Home treatment of deep venous thrombosis in patients with cancer. Haematologica 2005, 90:220\u2013224.","journal-title":"Haematologica"},{"key":"112_CR19","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","volume":"349","author":"The Matisse Investigators","year":"2003","unstructured":"The Matisse Investigators: Subcutaneous Fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003, 349:1695\u20131702.","journal-title":"N Engl J Med"},{"key":"112_CR20","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","volume":"140","author":"HR Buller","year":"2004","unstructured":"Buller HR, Davidson BL, Decousus H, et al.: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004, 140:867\u2013873.","journal-title":"Ann Intern Med"},{"key":"112_CR21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1160\/TH08-09-0563","volume":"101","author":"FF Doormaal van","year":"2009","unstructured":"van Doormaal FF, Raskob GE, Davidson BL, et al.: Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials. Thromb Haemost 2009, 101:762\u2013769.","journal-title":"Thromb Haemost"},{"key":"112_CR22","doi-asserted-by":"crossref","unstructured":"The EINSTEIN investigators, oral rivaroxaban for symptomatic Venous Thromboembolism. N Engl J Med 2010, 363:2499\u20132510.","DOI":"10.1056\/NEJMoa1007903"},{"key":"112_CR23","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Shulman","year":"2009","unstructured":"Shulman S, Kearon C, Kakkar AK, et al.: Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342\u20132352.","journal-title":"N Engl J Med"},{"key":"112_CR24","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2005-04-1508","volume":"106","author":"P Prandoni","year":"2005","unstructured":"Prandoni P: How I treat venous thromboembolism in cancer patients. Blood 2005, 106:4027\u20134033.","journal-title":"Blood"},{"key":"112_CR25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCULATIONAHA.104.512834","volume":"112","author":"PREPIC study group","year":"2005","unstructured":"PREPIC study group: Eight year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: The PREPIC randomized study. Circulation 2005, 112:416\u2013422.","journal-title":"Circulation"},{"issue":"15","key":"112_CR26","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","volume":"162","author":"G Meyer","year":"2002","unstructured":"Meyer G, Marjanovic Z, Valcke J, et al.: Comparison of low molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med 2002, 162(15):1729\u20131735.","journal-title":"Arch Intern Med"},{"issue":"2","key":"112_CR27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, et al.: Low-molecular weight heparin versus a coumarin for the prevention of venous thromboembolism in patients with cancer. N Engl J Med 2003, 349(2):146\u2013153.","journal-title":"N Engl J Med"},{"key":"112_CR28","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","volume":"119","author":"RD Hull","year":"2006","unstructured":"Hull RD, Pineo GF, Brant RF, et al.: For the Lite trial investigators. Long term low-molecular weight heparin versus usual care in proximal vein thrombosis patients with cancer. Am J Med 2006, 119:1062\u20131072.","journal-title":"Am J Med"},{"key":"112_CR29","doi-asserted-by":"crossref","unstructured":"Lee AY. Treating venous thromboembolism in cancer patients: the case for low-molecular weight heparins. In Cancer Associated Thrombosis edited by Khorana AA and Francis CW. Informa Healthcare. New York London. 2007. Chapter 16: 231\u2013242.","DOI":"10.3109\/9781420048001-17"},{"issue":"3","key":"112_CR30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-134-3-200102060-00009","volume":"134","author":"G Merli","year":"2001","unstructured":"Merli G, Spiro TE, Olsson CG, et al.: Subcutaneous enoxaparin once or twice daily compared with intravenous heparin for the treatment of venous thromboembolic disease. Ann Intern Med 2001, 134(3):191\u2013202.","journal-title":"Ann Intern Med"},{"key":"112_CR31","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJM200103013440902","volume":"344","author":"HK Breddin","year":"2001","unstructured":"Breddin HK, Hach-Wunderle V, Nakov R, et al.: Effects of a low molecular weight heparin on thrombus regression and recurrent venous thromboembolism in patients with DVT. N Engl J Med 2001, 344:626\u2013631.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"112_CR32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2003-45411","volume":"29","author":"P Prandoni","year":"2003","unstructured":"Prandoni P, Piccioli A, Pagnan A: Recurrent thromboembolism in cancer patients: incidence and risk factors. Semin Thromb Hemost 2003, 29(Suppl 1):3\u20138.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"112_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-125-1-199607010-00001","volume":"125","author":"P Prandoni","year":"1996","unstructured":"Prandoni P, Lensing AWA, Cogo A, et al.: The long term clinical course of acute deep venous thrombosis. Ann Intern Med 1996, 125(1):1\u20137.","journal-title":"Ann Intern Med"},{"key":"112_CR34","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","volume":"7","author":"M Carrier","year":"2009","unstructured":"Carrier M, Le Gal G, Cho R, et al.: Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009, 7:760\u2013765.","journal-title":"J Thromb Haemost"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-011-0112-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-011-0112-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-011-0112-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T18:59:57Z","timestamp":1559933997000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-011-0112-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,19]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["112"],"URL":"https:\/\/doi.org\/10.1007\/s11936-011-0112-2","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,19]]}}}